Using “IBD disability index” can help predict reduced work productivity associated with working while sick
Acknowledgement: This article is a summary of “Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada” recen...
Acknowledgement: This article is a summary of “Influences and Impact of Anxiety and Depression in the Setting of Inflammatory Bowel Disease” recently published in Inflammatory Bowel Diseases by Seyedehsan Navabi, MD, Venkata Subhash Gorrepati, MD, MPH, Sanjay Yadav, MD, Jaykrishna Chint...
The Crohn's & Colitis Foundation and RTI International are working together to conduct a survey of adult patients and caregivers of pediatric patients with inflammatory bowel disease. The goal of this survey is to understand why some patients choose to participate in clini...
Last month, Andres Hurtado-Lorenzo, Ph.D. Senior Director of Translational Research for the Crohn’s & Colitis Foundation, had an opportunity to present “Towards Precision Medicine in Inflammatory Bowel Diseases” at the 5th Precision Medicine and Biomarkers Leaders Summit in Munich.&...
Acknowledgement: This article is a summary of “Dietary Interventions to Modulate the Gut Microbiome— how far away are we from precision medicine” recently published in Inflammatory Bowel Diseases by Francesca De Filippis, PhD, Paola Vitaglione, PhD, Rosario Cuomo, MD, Roberto Bern...
IBD Qorus is the Crohn’s & Colitis Foundation’s quality improvement initiative designed to drive improved care and health outcomes for adult patients with IBD. Healthcare teams from centers across the United States come together to learn and share best practices for improved health ...
We know a topic of major interest within IBD community is the role that diet plays in the management of Crohn’s disease and ulcerative colitis. Unfortunately, there has been little scientific research into how diet may impact IBD but the good news is we are working to change that.
In 2...
Please briefly describe your research interests in the relationship between joint inflammation and gut inflammation.
Randy: Many IBD patients – up to one third - experience significant extra-intestinal manifestations of the disease. The most common is joint inflammation.&nbs...
Ever wonder what fecal microbiota transplantation is? Check out our latest vlog featuring Dr. Neil Nandi, Director of the Inflammatory Bowel Disease Center at Drexel University, College of Medicine.
Video Length
...
On May 30th of this year, the Food and Drug Administration (FDA) approved a new treatment for moderately to severely active ulcerative colitis. Tofacitinib, which is made by Pfizer Labs, was previously approved in 2012 for rheumatoid arthritis and in 2017 for psoriatic arthri...